2. Search Result
Search Result
Results for "

2-arachidonoylglycerol

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

3

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W011051
    2-Arachidonoylglycerol
    1 Publications Verification

    		 Cannabinoid Receptor Endogenous Metabolite Neurological Disease
    2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.
    2-Arachidonoylglycerol
  • HY-W011051S
    2-Arachidonoylglycerol-d8

    		Cannabinoid Receptor Endogenous Metabolite Neurological Disease
    2-Arachidonoylglycerol-d8 is the deuterium labeled 2-Arachidonoylglycerol. 2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.
    2-Arachidonoylglycerol-d8
  • HY-W011051S1
    2-Arachidonoylglycerol-d5

    		Cannabinoid Receptor Endogenous Metabolite Neurological Disease
    2-Arachidonoylglycerol-d5 is the deuterium labeled 2-Arachidonoylglycerol. 2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.
    2-Arachidonoylglycerol-d5
  • HY-15249
    JZL 184
    3 Publications Verification

    		 MAGL Neurological Disease
    JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC50 of 8 nM). JZL 184 displays >300-fold selectivity for MAGL over FAAH [2].
    JZL 184
  • HY-W013788
    2-Palmitoylglycerol

    2-Palm-Gl

    		 Cannabinoid Receptor Neurological Disease
    2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .
    2-Palmitoylglycerol
  • HY-133130
    JNJ-42226314

    		MAGL Neurological Disease
    JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain .
    JNJ-42226314
  • HY-W011051S2
    2-Arachidonoylglycerol-d11

    		Isotope-Labeled Compounds Cannabinoid Receptor Endogenous Metabolite Neurological Disease
    2-Arachidonoylglycerol-d11 is deuterium labeled 2-Arachidonoylglycerol.2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system[1].
    2-Arachidonoylglycerol-d11
  • HY-W013788R
    2-Palmitoylglycerol (Standard)

    		Cannabinoid Receptor Neurological Disease
    2-Palmitoylglycerol (Standard) is the analytical standard of 2-Palmitoylglycerol. This product is intended for research and analytical applications. 2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .
    2-Palmitoylglycerol (Standard)
  • HY-118653
    SAR629

    		MAGL Metabolic Disease
    SAR629 is a potent monoglyceride lipase (MGL) covalent inhibitor. SAR629 also inhibits 2-Arachidonoylglycerol (2-AG) degradation [2].
    SAR629
  • HY-112828
    LEI105

    		DAGL Neurological Disease Metabolic Disease Inflammation/Immunology
    LEI105 is a potent, highly selective and reversible dual diacylglycerol lipase (DAGL)-α/DAGL-β inhibitor. LEI105 reduces 2-arachidonoylglycerol levels in Neuro2A cells. LEI105 also reduces cannabinoid CB1-receptor-mediated short-term synaptic plasticity in a mouse hippocampal slice model. LEI105 is promising for research of diseases, such as obesity, related metabolic disorders and neuroinflammation .
    LEI105
  • HY-120300
    UCM710

    		Cannabinoid Receptor Metabolic Disease
    UCM710 is an endocannabinoid (eCB) hydrolysis inhibitor that increases the levels of N-arachidonoyl ethanolamine and 2-arachidonoylglycerol in neurons. UCM710 inhibits fatty acid amide hydrolase and α/β-hydrolase domain 6, but not monoacylglycerol lipase .
    UCM710
  • HY-117474
    MJN110
    2 Publications Verification

    		 MAGL Neurological Disease
    MJN110 is an orally active and selective monoacylglycerol lipase (MAGL) inhibitor with IC50s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively . MJN110 produces opioid-sparing effects and displays strong antihyperalgesic activity [2].
    MJN110
  • HY-158362A
    Monoglyceride lipase, Bacillus sp.

    		Endogenous Metabolite Neurological Disease Metabolic Disease Inflammation/Immunology
    Monoglyceride lipase, Bacillus sp., is a key enzyme involved in lipid metabolism. It catalyzes the hydrolysis of monoglycerides (particularly 2-AG, or 2-arachidonoylglycerol) into glycerol and free fatty acids. By regulating the levels of 2-AG, Monoglyceride lipase, Bacillus sp., can influence neural signaling, pain perception, inflammatory responses, and metabolic processes .
    Monoglyceride lipase, Bacillus sp.
  • HY-18540
    KT109

    		DAGL MAGL Metabolic Disease Inflammation/Immunology
    KT109 is a potent and an isoform-selective inhibitor of diacylglycerol lipase-β (DAGLβ) with an IC50 of 42 nM. KT109 has ~60-fold selectivity for DAGLβ over DAGLα. KT109 shows inhibitory activity against PLA2G7 (IC50=1 µM). KT109 shows negligible activity against FAAH, MGLL, ABHD11, and cytosolic phospholipase A2 (cPLA2 or PLA2G4A). KT109 perturbs a lipid network involved in macrophage inflammatory responses and lowers 2-arachidonoylglycerol (2-AG), arachidonic acid and eicosanoids in mouse peritoneal macrophages .
    KT109
  • HY-131995
    O-Arachidonoyl glycidol

    		Cannabinoid Receptor Metabolic Disease
    O-Arachidonoyl glycidol (compound 1) is a 2-arachidonoylglycerol (2-AG) analog. O-Arachidonoyl glycidol inhibits cytosolic 2-oleoylglycerol (2-OG) hydrolysis with an IC50 value of 4.5 µM. O-Arachidonoyl glycidol blocks 2-OG hydrolysis in membrane fractions and anandamide hydrolysis with IC50s of 19, 12 µM, respectively .
    O-Arachidonoyl glycidol
  • HY-103463
    SA57

    		FAAH MAGL Neurological Disease
    SA57 is a potent, selective FAAH inhibitor with IC50s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases MAGL (IC50s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC50 of 850 nM), but not other brain serine hydrolases [2].
    SA57
  • HY-130311
    2-Linoleoyl glycerol

    2-Monolinolein; 2-Monolinoleoylglycerol

    		 Cannabinoid Receptor Neurological Disease
    2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) [2].
    2-Linoleoyl glycerol
  • HY-124314
    LEI-106

    		DAGL MAGL Metabolic Disease
    LEI-106 is a potent, dual sn-1-Diacylglycerol lipase α (DAGL-α)/ABHD6 inhibitor with an IC50 of 18 nM for DAGL-α and a Ki of 0.8 μM for ABHD6. LEI-106 inhibits the hydrolysis of [ 14C]-sn-1-oleoyl-2-arachidonoyl-glycerol, the natural substrate of DAGL-α, with a Ki of 0.7 μM .
    LEI-106

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: